Published in Bone Marrow Transplant on October 22, 2007
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.72
Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant (2009) 1.27
Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission. Cancers (Basel) (2012) 0.81
New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant (2015) 0.80
Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplant (2015) 0.79
Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol (1997) 1.48
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) Blood (1995) 1.43
Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol (1994) 1.43
Economic evaluation of peripheral blood stem cell transplantation for lymphoma. Lancet (1992) 1.40
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia (2009) 1.29
Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet (1993) 1.24
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant (2010) 1.16
Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol (2001) 1.10
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant (2008) 1.08
Pregnancy associated aplastic anaemia: a report of five cases and review of current management. Br J Haematol (1989) 1.08
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol (2003) 1.05
Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia (2009) 1.01
Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A. Bone Marrow Transplant (1992) 1.01
Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol (1995) 0.99
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia (2006) 0.98
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant (2005) 0.98
Abnormal fibrinolytic activity in systemic lupus erythematosus and possible mechanisms. Br J Rheumatol (1988) 0.98
Bone marrow transplantation: current situation, complications and prevention. J Antimicrob Chemother (1995) 0.97
Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment. Leukemia (2005) 0.97
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol (2004) 0.94
Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant (2011) 0.94
Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia (1995) 0.93
Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol (1998) 0.89
Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant (2001) 0.89
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol (1997) 0.89
Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant (2007) 0.88
Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer (1994) 0.88
Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant (1993) 0.87
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia (2010) 0.87
Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia (2004) 0.86
Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant (1995) 0.86
Extramedullary haemopoiesis as a cause of mediastinal lymphadenopathy in chronic myelomonocytic leukaemia. Clin Lab Haematol (1990) 0.86
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy (2001) 0.86
Thrombocytopathy in preleukaemia: association with a defect of thromboxane A2 activity. Br J Haematol (1979) 0.85
A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course. Br J Haematol (1998) 0.85
Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia (1999) 0.84
Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia (2003) 0.84
Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant (1997) 0.84
The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant (2000) 0.84
Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol (1994) 0.84
An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. Cytotherapy (2000) 0.83
Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia (1997) 0.83
Heterogeneous mechanisms of autocrine growth of AML blasts. Br J Haematol (1989) 0.82
Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol (1996) 0.82
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol (2000) 0.82
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia (2012) 0.82
Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol (1994) 0.82
Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol (2005) 0.81
Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34. Cytometry (1999) 0.81
Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients. J Hosp Infect (2002) 0.81
Effect of erythropoietin in patients with myeloma. BMJ (1990) 0.81
DNA repair mechanisms and acute myeloblastic leukemia. Hematol Oncol (2000) 0.80
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial. Br J Haematol (1992) 0.80
Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Bone Marrow Transplant (2003) 0.80
Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect. Br J Haematol (2000) 0.79
Successful therapy with ribavirin of late onset respiratory syncytial virus pneumonitis complicating allogeneic bone transplantation. Clin Lab Haematol (1992) 0.79
Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leuk Lymphoma (1997) 0.79
Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. J Clin Oncol (1997) 0.79
Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol (1995) 0.79
Macrophage-inflammatory protein-1alpha receptor expression on normal and chronic myeloid leukemia CD34+ cells. J Immunol (1999) 0.79
High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma. Leuk Res (2007) 0.78
Cerebral vasculitis associated with hairy cell leukemia. Cancer (1987) 0.78
Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection. Clin Mol Pathol (1996) 0.78
Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure. Br J Cancer (1990) 0.78
The effect of deoxycoformycin and deoxyadenosine on deoxyribonucleotide concentrations in leukaemic cells. Br J Haematol (1982) 0.78
Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia. Lancet (1981) 0.78
Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. Bone Marrow Transplant (2009) 0.78
Studies on the biochemical sequelae of therapy in Thy-acute lymphoblastic leukaemia with the adenosine deaminase inhibitor 2' deoxycoformycin. Br J Haematol (1981) 0.77
Comparative study of CD34-positive cells and subpopulations in human umbilical cord blood and bone marrow. Bone Marrow Transplant (1993) 0.77
Naso-jejunal feeding in allogeneic bone marrow transplant recipients: results of a pilot study. Bone Marrow Transplant (2001) 0.77
Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Bone Marrow Transplant (1998) 0.77
Peripheral blood stem cell transplants. J Clin Pathol (1998) 0.77
Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant (1995) 0.77
Functional multidrug resistance in acute myeloblastic leukaemia: a standardized flow cytometric assay for intracellular daunorubicin accumulation. Br J Haematol (1998) 0.77
Interaction of aluminium and gallium with human lymphocytes: the role of transferrin. Biochim Biophys Acta (1991) 0.77
IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. Br J Haematol (2008) 0.76
Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. Thromb Res (1981) 0.76
Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemia. Br J Haematol (1990) 0.76
Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect. Bone Marrow Transplant (1997) 0.76
Allogeneic bone marrow transplant for multiple myeloma. Blood (1997) 0.76
Peripheral blood stem cells for allogeneic transplantation. Bone Marrow Transplant (1994) 0.76
Thrombocytopathy associated with autoimmune haemolytic anaemia. Br Med J (1978) 0.76
Treatment of acute myeloid leukaemia in a renal allograft recipient: implications of cyclosporin immunosuppressive treatment. J Clin Pathol (1991) 0.75
Anticorresponding p15 promoter methylation and microsatellite instability in acute myeloblastic leukemia. Blood (2000) 0.75
Sensitivity of S. cerevisiae in haematology patients. J Hosp Infect (2001) 0.75
G-CSF dosage and scheduling following autologous PBSC transplantation. Bone Marrow Transplant (1998) 0.75
In vivo Campath for the prevention of GvHD following allogeneic HSCT: effects of dose, schedule and antibody type. Bone Marrow Transplant (2004) 0.75
Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma. Bone Marrow Transplant (1998) 0.75
Second allogeneic transplant for severe aplastic anaemia following late graft rejection. Br J Haematol (1999) 0.75
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in lymphoma without blood product support. Bone Marrow Transplant (2000) 0.75
Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8. Br J Haematol (1998) 0.75
Peripheral blood stem cells from unrelated donors for allogeneic transplantation. Transplantation (1999) 0.75